Vestcor Inc Has $475,000 Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Vestcor Inc raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 540.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,578 shares of the specialty pharmaceutical company's stock after acquiring an additional 13,990 shares during the period. Vestcor Inc owned approximately 0.05% of Collegium Pharmaceutical worth $475,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in COLL. AlphaQuest LLC raised its stake in shares of Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after buying an additional 374 shares in the last quarter. Kendall Capital Management grew its holdings in shares of Collegium Pharmaceutical by 31.6% in the 4th quarter. Kendall Capital Management now owns 17,760 shares of the specialty pharmaceutical company's stock worth $509,000 after acquiring an additional 4,260 shares during the last quarter. Amundi raised its position in Collegium Pharmaceutical by 188.3% during the fourth quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company's stock valued at $446,000 after buying an additional 10,168 shares during the period. Raymond James Financial Inc. acquired a new position in Collegium Pharmaceutical during the fourth quarter valued at $2,432,000. Finally, Aigen Investment Management LP acquired a new position in Collegium Pharmaceutical during the fourth quarter valued at $230,000.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 977 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares in the company, valued at approximately $4,928,070. This trade represents a 0.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares of the company's stock, valued at $3,732,630. This represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,193 shares of company stock worth $3,243,594. 3.98% of the stock is currently owned by company insiders.

Remove Ads

Collegium Pharmaceutical Stock Up 0.3 %

Shares of COLL traded up $0.08 during trading hours on Thursday, hitting $29.93. 413,289 shares of the company were exchanged, compared to its average volume of 412,259. The company has a market cap of $942.38 million, a PE ratio of 12.90 and a beta of 0.99. The firm's 50 day moving average is $30.82 and its 200-day moving average is $32.79. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. On average, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on COLL shares. Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target on the stock in a research report on Friday, January 10th. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.